153 related articles for article (PubMed ID: 29574251)
21. Study on the role of G1 cyclins in Epstein-Barr virus-associated human lymphomas maintained in severe combined immune deficiency (SCID) mice.
Murai Y; Dobashi Y; Okada E; Ishizawa S; Shiota M; Mori S; Takano Y
Int J Cancer; 2001 Apr; 92(2):232-9. PubMed ID: 11291051
[TBL] [Abstract][Full Text] [Related]
22. Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies.
Jäger W; Xue H; Hayashi T; Janssen C; Awrey S; Wyatt AW; Anderson S; Moskalev I; Haegert A; Alshalalfa M; Erho N; Davicioni E; Fazli L; Li E; Collins C; Wang Y; Black PC
Oncotarget; 2015 Aug; 6(25):21522-32. PubMed ID: 26041878
[TBL] [Abstract][Full Text] [Related]
23. Experimental infection of NOD/SCID mice reconstituted with human CD34+ cells with Epstein-Barr virus.
Islas-Ohlmayer M; Padgett-Thomas A; Domiati-Saad R; Melkus MW; Cravens PD; Martin Mdel P; Netto G; Garcia JV
J Virol; 2004 Dec; 78(24):13891-900. PubMed ID: 15564497
[TBL] [Abstract][Full Text] [Related]
24. Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
Stewart EL; Mascaux C; Pham NA; Sakashita S; Sykes J; Kim L; Yanagawa N; Allo G; Ishizawa K; Wang D; Zhu CQ; Li M; Ng C; Liu N; Pintilie M; Martin P; John T; Jurisica I; Leighl NB; Neel BG; Waddell TK; Shepherd FA; Liu G; Tsao MS
J Clin Oncol; 2015 Aug; 33(22):2472-80. PubMed ID: 26124487
[TBL] [Abstract][Full Text] [Related]
25. Patient-derived xenografts of gastrointestinal cancers are susceptible to rapid and delayed B-lymphoproliferation.
Dieter SM; Giessler KM; Kriegsmann M; Dubash TD; Möhrmann L; Schulz ER; Siegl C; Weber S; Strakerjahn H; Oberlack A; Heger U; Gao J; Hartinger EM; Oppel F; Hoffmann CM; Ha N; Brors B; Lasitschka F; Ulrich A; Strobel O; Schmidt M; von Kalle C; Schneider M; Weichert W; Ehrenberg KR; Glimm H; Ball CR
Int J Cancer; 2017 Mar; 140(6):1356-1363. PubMed ID: 27935045
[TBL] [Abstract][Full Text] [Related]
26. Spontaneous Post-Transplant Disorders in NOD.Cg- Prkdcscid Il2rgtm1Sug/JicTac (NOG) Mice Engrafted with Patient-Derived Metastatic Melanomas.
Radaelli E; Hermans E; Omodho L; Francis A; Vander Borght S; Marine JC; van den Oord J; Amant F
PLoS One; 2015; 10(5):e0124974. PubMed ID: 25996609
[TBL] [Abstract][Full Text] [Related]
27. Rituximab Decreases Lymphoproliferative Tumor Formation in Hepatopancreaticobiliary and Gastrointestinal Cancer Patient-Derived Xenografts.
Leiting JL; Hernandez MC; Yang L; Bergquist JR; Ivanics T; Graham RP; Truty MJ
Sci Rep; 2019 Apr; 9(1):5901. PubMed ID: 30976061
[TBL] [Abstract][Full Text] [Related]
28. [Molecular pathological characteristics of human B-cell lymphomas induced by Epstein-Barr virus].
Gan RL; Yin ZH; Liu TF; Dong BH; Zhou JG; Yao KT
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Oct; 35(10):925-9. PubMed ID: 14515211
[TBL] [Abstract][Full Text] [Related]
29. Epstein-Barr virus-induced human B-cell lymphoma arising in HuPBL-SCID chimeric mice: characterization and the role of CD40 stimulation in their treatment and prevention.
Funakoshi S; Beckwith M; Fanslow W; Longo DL; Murphy WJ
Pathobiology; 1995; 63(3):133-42. PubMed ID: 8821629
[TBL] [Abstract][Full Text] [Related]
30. Colorectal cancer patient-derived xenografted tumors maintain characteristic features of the original tumors.
Cho YB; Hong HK; Choi YL; Oh E; Joo KM; Jin J; Nam DH; Ko YH; Lee WY
J Surg Res; 2014 Apr; 187(2):502-9. PubMed ID: 24332554
[TBL] [Abstract][Full Text] [Related]
31. Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors.
Wang D; Pham NA; Tong J; Sakashita S; Allo G; Kim L; Yanagawa N; Raghavan V; Wei Y; To C; Trinh QM; Starmans MH; Chan-Seng-Yue MA; Chadwick D; Li L; Zhu CQ; Liu N; Li M; Lee S; Ignatchenko V; Strumpf D; Taylor P; Moghal N; Liu G; Boutros PC; Kislinger T; Pintilie M; Jurisica I; Shepherd FA; McPherson JD; Muthuswamy L; Moran MF; Tsao MS
Int J Cancer; 2017 Feb; 140(3):662-673. PubMed ID: 27750381
[TBL] [Abstract][Full Text] [Related]
32. Development of Patient Derived Xenograft Models of Overt Spontaneous Breast Cancer Metastasis: A Cautionary Note.
Paez-Ribes M; Man S; Xu P; Kerbel RS
PLoS One; 2016; 11(6):e0158034. PubMed ID: 27355476
[TBL] [Abstract][Full Text] [Related]
33. Diffuse large B-cell primary gastric lymphoma treated successfully with the CD20 monoclonal antibody (rituximab): a case with severe liver dysfunction due to liver cirrhosis and hepatocellular carcinoma.
Nakai S; Masaki T; Shintani T; Deguchi A; Kimura Y; Himoto T; Kurokohchi K; Watanabe S; Kuriyama S
Oncol Rep; 2005 Jun; 13(6):1065-8. PubMed ID: 15870922
[TBL] [Abstract][Full Text] [Related]
34. Rituximab in the treatment of EBV-positive low grade B-cell lymphoma.
Diamantopoulos PT; Polonyfi K; Sofotasiou M; Papadopoulou V; Kalala F; Iliakis T; Zervakis K; Tsilimidos G; Kouzis P; Kyrtsonis MC; Vassilakopoulos T; Angelopoulou M; Siakantaris M; Vayopoulos G; Kollia P; Pangalis G; Viniou NA
Anticancer Res; 2013 Dec; 33(12):5693-8. PubMed ID: 24324119
[TBL] [Abstract][Full Text] [Related]
35. LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesis.
Ma SD; Xu X; Plowshay J; Ranheim EA; Burlingham WJ; Jensen JL; Asimakopoulos F; Tang W; Gulley ML; Cesarman E; Gumperz JE; Kenney SC
J Clin Invest; 2015 Jan; 125(1):304-15. PubMed ID: 25485679
[TBL] [Abstract][Full Text] [Related]
36. Establishing a cryopreservation protocol for patient-derived xenografts of prostate cancer.
Porter LH; Lawrence MG; Wang H; Clark AK; Bakshi A; Obinata D; Goode D; Papargiris M; Mural ; Clouston D; Ryan A; Norden S; Corey E; Nelson PS; Isaacs JT; Grummet J; Kourambas J; Sandhu S; Murphy DG; Pook D; Frydenberg M; Taylor RA; Risbridger GP
Prostate; 2019 Aug; 79(11):1326-1337. PubMed ID: 31212368
[TBL] [Abstract][Full Text] [Related]
37. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
Risbridger GP; Taylor RA; Clouston D; Sliwinski A; Thorne H; Hunter S; Li J; Mitchell G; Murphy D; Frydenberg M; Pook D; Pedersen J; Toivanen R; Wang H; Papargiris M; Lawrence MG; Bolton DM
Eur Urol; 2015 Mar; 67(3):496-503. PubMed ID: 25154392
[TBL] [Abstract][Full Text] [Related]
38. Imatinib mesylate reduces rituximab-induced tumor-growth inhibition in vivo on Epstein-Barr virus-associated human B-cell lymphoma.
Némati F; Mathiot C; Grandjean I; Lantz O; Bordier V; Dewulf S; Ekue R; Di Santo JP; Poupon MF; Decaudin D
Anticancer Drugs; 2007 Oct; 18(9):1029-37. PubMed ID: 17704653
[TBL] [Abstract][Full Text] [Related]
39. Knockout of Epstein-Barr virus BPLF1 retards B-cell transformation and lymphoma formation in humanized mice.
Whitehurst CB; Li G; Montgomery SA; Montgomery ND; Su L; Pagano JS
mBio; 2015 Oct; 6(5):e01574-15. PubMed ID: 26489865
[TBL] [Abstract][Full Text] [Related]
40. Epstein-Barr virus latent membrane protein-1 protects B-cell lymphoma from rituximab-induced apoptosis through miR-155-mediated Akt activation and up-regulation of Mcl-1.
Kim JH; Kim WS; Park C
Leuk Lymphoma; 2012 Aug; 53(8):1586-91. PubMed ID: 22268450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
